Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus vinorelbine in HER2-intermediate metastatic breast cancer after first-line failure
2011-001765-41Phase 2Terminated
- Sponsor
- Medical Faculty Magdeburg
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and vinorelbine in breast cancer, sponsored by Medical Faculty Magdeburg. Primary endpoint: Progression-free survival. Started Oct 2011; status: terminated.
02
Drugs
afatinibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-001765-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001765-41.